|1.||Venketasubramanian, Narayanaswamy: 8 articles (01/2016 - 01/2013)|
|2.||Venketasubramanian, N: 8 articles (08/2013 - 01/2008)|
|3.||Chen, Christopher L H: 7 articles (01/2016 - 01/2013)|
|4.||Wong, K S Lawrence: 6 articles (01/2016 - 08/2013)|
|5.||Lee, Chun Fan: 6 articles (01/2016 - 08/2013)|
|6.||Navarro, Jose C: 5 articles (04/2015 - 01/2012)|
|7.||Chan, Bernard P L: 5 articles (01/2015 - 01/2008)|
|8.||Heurteaux, C: 5 articles (09/2014 - 06/2010)|
|9.||Lazdunski, M: 5 articles (09/2014 - 06/2010)|
|10.||Chen, Christopher: 5 articles (01/2013 - 01/2008)|
01/01/2009 - "Our aim was to investigate the efficacy of Neuroaid on motor recovery in ischemic stroke patients using rehabilitation endpoints in accordance with the International Conference on Harmonization/Good Clinical Practice guidelines, in order to provide predictive information for further larger trials. "
08/01/2013 - "The Chinese Medicine Neuroaid Efficacy on Stroke recovery (CHIMES) study tested the hypothesis that MLC601 is superior to placebo in acute, moderately severe ischemic stroke within a 72-hour time window. "
01/01/2013 - "Chinese medicine NeuroAiD efficacy stroke recovery-extension study (CHIMES-E study): an observational multicenter study to investigate the longer-term efficacy of NeuroAiD in stroke recovery."
01/01/2016 - "Analyses were performed using data from an international, double-blind randomized controlled trial investigating the efficacy of MLC601 on stroke recovery in patients with ischemic stroke of intermediate severity (Chinese Medicine Neuroaid Efficacy on Stroke recovery [CHIMES]). "
08/01/2015 - "The value of patient selection in demonstrating treatment effect in stroke recovery trials: lessons from the CHIMES study of MLC601 (NeuroAiD)."
01/01/2013 - "This extension study tests the hypothesis that at 2 years, an initial 3-month administration of NeuroAiD is superior to placebo in reducing neurological deficit and improving functional outcome in patients with cerebral infarction of an intermediate range of severity. "
02/01/2009 - "Aim This study tests the hypothesis that Neuroaid, a TCM widely used in China post-stroke, is superior to placebo in reducing neurological deficit and improving functional outcome in patients with acute cerebral infarction of an intermediate severity. "
08/01/2013 - "To test the hypothesis that the efficacy of NeuroAiD compared with placebo in improving functional outcome and reducing neurological deficit in patients with cerebral infarction of intermediate severity varies between sub-groups of patients randomized in the main Chinese Medicine Neuroaid Efficacy on Stroke study when categorized according to baseline imaging characteristics. "
01/01/2015 - "The CHInese Medicine NeuroAiD Efficacy on Stroke recovery (CHIMES) study was an international randomized double-blind placebo-controlled trial of MLC601 (NeuroAiD) in subjects with cerebral infarction of intermediate severity within 72 h. "
01/01/2013 - "NeuroAiD demonstrated both neuroprotective and neuroregenerative properties in rodent models of focal and global ischemia and in cortical cell cultures. "
06/01/2010 - "Here, we demonstrate in a rodent model of focal ischemia that NeuroAid II (MLC901) pre- and post-treatments up to 3 h after stroke improve survival, protect the brain from the ischemic injury and drastically decrease functional deficits. "
01/01/2013 - "NeuroAiD improved survival, attenuated infarct size, improved functional recovery in the model of focal ischemia, and protected neurons against glutamate-induced injury. "
09/01/2012 - "NeuroAid (MLC601 and MLC901), a Traditional Medicine used in China for patients after stroke has been reported in preclinical models of ischemia to induce neuroprotection and neuroplasticity. "
|4.||Brain Injuries (Brain Injury)
|2.||Glutamic Acid (Glutamate)
|3.||danqi piantang jiaonang
|1.||Chinese Traditional Medicine (Traditional Chinese Medicine)
|2.||Complementary Therapies (Alternative Medicine)
|3.||Traditional Medicine (Folk Remedies)